Teva Pharmaceutical Indus 株価情報 (NYSE: TEVA)

最新ニュース Teva Pharmaceutical Indus (NYSE:TEVA) 株価情報

Teva Pharmaceutical Indus

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Industries Ltd

TEVA PHARM INDUS LTD ORD by Teva Pharmaceutical Industries Ltd.

TEVANO SYS HLDGS INC by Tevano Systems Holdings Inc.

Tevano Systems Holdings Inc

Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) has filed a lawsuit contesting the <a href="https://www.benzinga.com/topic/inflation-reduction-act">Inflation Reduction Act </a>of 2022, targeting its drug-pricing provisions and the Centers for Medicare &amp; Medicaid Services&#8217; implementation of the program.
The company <a target="_blank" href="https://storage.courtlistener.com/recap/gov.uscourts.dcd.276490/gov.uscourts.dcd.276490.1.0.pdf" rel="noreferrer noopener">argues</a> that the law undermines pharmaceutical innovation and the delicate balance between affordability and competition in the U.S. healthcare system.
Teva&#8217;s complaint highlights its dual role as a developer of therapies and provider of lower-cost generics and biosimilars.
The company contends that the IRA's Drug Price Negotiation Program (DPNP) disrupts free-market competition by enabling CMS to impose price controls without a statutory basis, a move Teva deems unconstitutional.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" rel="noreferrer noopener">Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases</a>
According to the lawsuit, the DPNP, framed as a negotiation process, functions more like a price mandate, leaving manufacturers with no viable alternatives but to comply.
Key to Teva&#8217;s challenge is CMS&#8217;s interpretation of what constitutes a &#8220;Qualifying Single Source Drug,&#8221; which determines when a drug becomes subject to price controls.
Teva claims CMS expanded the definition beyond congressional intent by including drugs with the same active molecule but approved under different FDA applications. This redefinition accelerates price control timelines, diminishing the competitive window for generics and biosimilars to gain market traction.
Additionally, Teva criticizes CMS&#8217;s &#8220;bona fide marketing&#8221; standard, which replaces Congress&#8217;s clear criteria for determining when a generic or biosimilar competitor ends price control eligibility. The standard introduces subjective and unpredictable assessments, prolonging price control periods for branded drugs and impairing generics' ability to compete on cost.
Teva&#8217;s lawsuit seeks injunctive and declaratory relief to protect its operations and the broader public health ecosystem, emphasizing the need to balance innovation incentives with cost-effective healthcare solutions.
Price Action: TEVA is up 0.85% at $21.86 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/43062308/fda-approves-astrazenecas-calquence-combo-therapy-for-untreated-mantle-cell-lymphoma" target="_blank" rel="noreferrer noopener">FDA Approves AstraZeneca&#8217;s Calquence Combo Therapy For Untreated Mantle Cell Lymphoma</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Biotech

Large Cap

News

Health Care

Legal

General

TEVA

Teva Challenges Drug Price Law's Impact On Innovation, Generics

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under Medicare Part D for price negotiations, building on efforts to reduce <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets" rel="noreferrer noopener">prescription drug costs</a>.
These negotiations, mandated by the Inflation Reduction Act, will take place in 2025, with the new prices slated to take effect in 2027.
The selected drugs, used to treat conditions like cancer, diabetes, and asthma, represented approximately $41 billion in Medicare Part D costs between November 2023 and October 2024, accounting for 14% of the program's total expenses.
Under the finalized <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/hhs-announces-15-additional-drugs-selected-medicare-drug-price-negotiations-continued-effort-lower" rel="noreferrer noopener">guidance</a> for the second negotiation cycle, drug manufacturers have until February 28, 2025, to decide on their participation.
The selected drug list for the second cycle of negotiations is:&nbsp;
<ul>
<li>Novo Nordisk's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) diabetes and weight loss drugs, Ozempic, Rybelsus, and Wegovy.</li>
<li>Pfizer Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Ibrance for breast cancer and Xtandi for prostate cancer.</li>
<li>GSK Plc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) Asthma and Chronic obstructive pulmonary disease treatment Trelegy Ellipta and Breo Ellipta.</li>
<li>Teva Pharmaceutical Industries Ltd.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) Huntington's disease and Tardive dyskinesia drug Austedo, Austedo XR.</li>
<li>Abbvie Inc.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) irritable bowel syndrome treatment Linzess and depression drug Vraylar.</li>
<li>Bristol-Myers Squibb Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Pomalyst for a type of blood cancer.</li>
<li>Boehringer Ingelheim's lung disease drug Ofev and diabetes med Tradjenta.</li>
<li>AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) cancer drug Calquence</li>
<li>Salix Pharmaceuticals' irritable bowel syndrome drug Xifaxan</li>
<li>Merck &amp; Co Inc's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) diabetes drug Janumet; Janumet XR.</li>
<li>Amgen Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) psoriasis drug Otezla</li>
</ul>
CMS will evaluate factors such as the drug's clinical benefit, its role in addressing unmet medical needs, and its impact on specific populations, alongside considerations for research, production, and distribution costs.
The first negotiation cycle in 2023 resulted in agreements for price reductions on 10 drugs, with discounts ranging from 38% to 79% off list prices.
The new prices, effective January 2026, are expected to save $6 billion in prescription drug costs annually and reduce out-of-pocket expenses for Medicare beneficiaries by an <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41166018/medicare-drug-price-negotiation-program-gets-final-guidance-for-second-cycle-1-5b-savings-expecte" rel="noreferrer noopener">estimated $1.5 billion</a>.
Looking ahead, CMS plans to expand the program, selecting up to 15 additional drugs for the third cycle and 20 more in subsequent cycles. The Inflation Reduction Act also introduces an out-of-pocket cap of $2,000 for Medicare Part D enrollees starting in 2025. Approximately 11 million beneficiaries are expected to benefit from the cap, saving a projected $7.2 billion annually.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43055401/schlumberger-posts-strong-q4-results-raises-dividend-and-buybacks-championx-deal-to-strengthen-future-growth" target="_blank" rel="noreferrer noopener">Schlumberger Q4: Earnings Beat, Dividend Boost, Offshore Boom And More</a></li>
</ul>
Image via Shutterstock

Government

Regulations

ABBV

AMGN

Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan raised the price target for Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) from $108 to $124. JP Morgan analyst Kian Abouhossein maintained a Neutral rating. Morgan Stanley shares closed at $135.81 on Thursday. <a href="https://www.benzinga.com/quote/MS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group slashed Bank of America Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) price target from $53 to $51. Evercore ISI Group analyst Glenn Schorr maintained an Outperform rating. Bank of America shares closed at $46.64 on Thursday. <a href="https://www.benzinga.com/quote/BAC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barrington Research raised the price target for Universal Technical Institute, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTI#NYSE">UTI</a>) from $25 to $30. Barrington Research analyst Alexander Paris maintained an Outperform rating. Universal Technical Institute shares closed at $26.00 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Guggenheim increased the price target for Natera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) from $170 to $200. Guggenheim analyst Subbu Nambi maintained a Buy rating. Natera shares closed at $168.50 on Thursday. <a href="https://www.benzinga.com/quote/NTRA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo cut Texas Instruments Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) price target from $208 to $200. Wells Fargo analyst Joe Quatrochi maintained an Equal-Weight rating. Texas Instruments shares settled at $187.37 on Thursday. <a href="https://www.benzinga.com/quote/TXN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Northland Capital Markets raised Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) price target from $35 to $41. Northland Capital Markets analyst Michael Latimore maintained an Outperform rating. Symbotic shares closed at $31.82 on Thursday. <a href="https://www.benzinga.com/quote/SYM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Barclays increased NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) price target from $160 to $175. Barclays analyst Blayne Curtis maintained an Overweight rating. Nvidia shares closed at $133.57 on Thursday.  <a href="https://www.benzinga.com/quote/NVDA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised the price target for Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) from $23 to $30. Piper Sandler analyst David Amsellem maintained an Overweight rating. Teva Pharmaceutical shares settled at $21.68 on Thursday. <a href="https://www.benzinga.com/quote/TEVA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan raised Planet Fitness, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) price target from $90 to $100. JP Morgan analyst Rahul Krotthapalli maintained an Overweight rating. Planet Fitness shares closed at $105.98 on Thursday. <a href="https://www.benzinga.com/quote/PLNT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods cut KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) price target from $85 to $76. Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintained a Market Perform rating. KB Home shares closed at $68.25 on Thursday. <a href="https://www.benzinga.com/quote/KBH/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43049593/slb-jb-hunt-transport-and-3-stocks-to-watch-heading-into-friday">SLB, J.B. Hunt Transport And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>

Price Target

Markets

Analyst Ratings

Trading Ideas

NTRA

NVDA

PLNT

Nvidia To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Friday

<a href="https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html" title="https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html">https://www.cnbc.com/2025/01/17/medicare-drug-price-negotiations-list-includes-ozempic.html</a>

'Ozempic Is In The Next Round Of Medicare Drug Price Negotiations. See The Full List Of 15 Medications' - CNBC

Piper Sandler analyst David Amsellem maintains Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) with a Overweight and raises the price target from $23 to $30.

Piper Sandler Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $30

<ul>
<li>Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea&#xAE;1</li>
<li>Agreement builds on the proven and successful collaboration of commercialization of FYB201, Formycon's biosimilar to Lucentis&#xAE;2 (ranibizumab) in Europe</li>
<li>The partnership broadens Teva's biosimilars portfolio, in line with its Pivot to Growth strategy &nbsp;</li>
</ul>

Teva Partners With Formycon And Klinge To Commercialize Biosimilar To Eylea In Europe And Israel

FDA Says Teva Pharmaceuticals USA's Ethinyl Estradiol; Norethindrone Tablet, Chewable Has Been Discontinued

Samsung Bioepis And Teva Enter Partnership For Commercialization Of EPYSQLI In US; Samsung Bioepis Will Be Responsible For Development, Regulatory Registration, Manufacture And Supply Of The Product, While Teva Will Be Responsible For Commercialization

On Wednesday, Catalyst Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>).
This Agreement resolves the patent litigation brought by Catalyst and its licensor SERB S.A in response to Teva&#8217;s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Firdapse (amifampridine) 10 mg tablets before the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42881700/catalyst-pharmaceuticals-announces-settlement-of-firdapse-amifampridine-patent-litigation-with-tev" rel="noreferrer noopener">expiration of the applicable patents</a>.
If approved by the FDA, Teva will not market its generic version of Firdapse in the United States before February 25, 2035, unless certain limited circumstances customarily included in these types of agreements occur.
The parties will terminate all ongoing patent litigation between Catalyst/SERB and Teva regarding Firdapse patents pending in the U.S. District Court for the District of New Jersey.
The ongoing Firdapse patent litigation involves two defendants: Hetero, which is being challenged on all of Firdapse&#8217;s Orange Book-listed patents, and Lupin, which is facing a case focused on Catalyst&#8217;s Firdapse patent that expires in 2037.
In the Notice Letter in January 2023, Teva stated that it intended to market a generic version of Firdapse before the expiration of multiple of Catalyst&#8217;s patents listed in the <a target="_blank" href="https://www.benzinga.com/news/23/01/30523209/why-catalyst-pharmaceuticals-shares-are-moving" rel="noreferrer noopener">FDA Orange Book</a>.
In May, the FDA approved its supplemental New Drug Application, increasing the indicated maximum daily dose of Firdapse&#8217;s (amifampridine) for adults and pediatric patients weighing more than 45 kg from 80 mg to 100 mg for Lambert-Eaton myasthenic syndrome (LEMS).
LEMS is a rare autoimmune disorder characterized by muscle weakness and fatigue. Firdapse is a potassium channel blocker indicated for LEMS in adults and pediatric patients six years of age and older and works by increasing the release of acetylcholine, a neurotransmitter, at the neuromuscular junction, which helps improve muscle <a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/g39094213/catalyst-pharmaceuticals-receives-u-s-fda-approval-for-increased-maximum-daily-dose-for-firdapse" rel="noreferrer noopener">function in people with LEMS</a>.
In the third quarter of 2024, Firdapse revenues increased 19.7% year over year to $79.3&nbsp;million. The company expects full-year 2024 net product revenue of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41787062/catalyst-pharmaceuticals-reports-strong-third-quarter-2024-financial-results-and-provides-corporat" rel="noreferrer noopener">$300 million—$310 million</a>.
Price Action: CPRX stock closed at $19.53 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/asset-sales/25/01/42896830/clear-channel-outdoor-plans-375-million-debt-repayment-following-625-million-sale-of-european-operations" target="_blank" rel="noreferrer noopener">Clear Channel Outdoor Plans $375 Million Debt Repayment Following $625 Million Sale of European Operations</a></li>
</ul>

CPRX

Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.A. ("SERB") have entered into a Settlement Agreement (Agreement) with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. (collectively Teva). This Agreement resolves the patent litigation brought by Catalyst and SERB in response to Teva's Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of FIRDAPSE&#xAE; (amifampridine) 10 mg tablets prior to expiration of the applicable patents.
Pursuant to the terms of the Agreement, Teva will not market its generic version of FIRDAPSE in the United States any earlier than February 25, 2035, if approved by the U.S. Food and Drug Administration (FDA), unless certain limited circumstances customarily included in these types of agreements occur. In accordance with the Agreement, the parties will terminate all ongoing patent litigation between Catalyst/SERB and Teva regarding FIRDAPSE patents pending in the U.S. District Court for the District of New Jersey. The pending FIRDAPSE patent litigation against the remaining defendants, Hetero (for all of FIRDAPSE's Orange Book-listed patents) and Lupin (only for Catalyst's FIRDAPSE patent expiring in 2037), is ongoing.
As required by law, the companies will submit the confidential license agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.
 &nbsp;

Contracts

Catalyst Pharmaceuticals Announces Settlement Of FIRDAPSE Patent Litigation With Teva Pharmaceuticals; Teva Will Not Market Its Generic Version Of FIRDAPSE In The U.S. Any Earlier Than February 25, 2035, If Approved By The FDA

Teva Pharmaceuticals USA's Ezetimibe And Simvastatin, Tablet, 10 Mg; 10 Mg, 10 Mg; 20 Mg, 10 Mg; 20 Mg Discontinued

CVS Health Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) subsidiary, Aetna Inc., has filed a lawsuit against more than 20 generic drug manufacturers. The lawsuit alleges a coordinated scheme to fix prices, <a href="https://www.benzinga.com/topic/drug-prices">allocate markets, and stifle competition</a>.
The result was a significant overcharge for essential medications.
Defendants include Teva Pharmaceutical Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), Amneal Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRX#NASDAQ">AMRX</a>), Dr. Reddy&#8217;s Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>), Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Viatris, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>), among others.
The <a target="_blank" href="https://civilinquiry.jud.ct.gov/DocumentInquiry/DocumentInquiry.aspx?DocumentNo=29056426" rel="noreferrer noopener">lawsuit</a> accuses the defendants of orchestrating one of the largest price-fixing conspiracies in U.S. history, causing inflated drug prices and widespread harm to consumers, insurers, and the healthcare system.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42600472/your-healthcare-costs-are-soaring-us-spending-reached-5-trillion-in-2023-with-major-increase-in-obesity-and-diabetes-drugs-hospital-services" rel="noreferrer noopener">Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services</a>
The lawsuit claims that these pharmaceutical companies colluded to artificially raise generic drug prices by as much as 2,762%.
Examples include clomipramine (2,600% increase), nadolol (+2,762%), and oxybutynin chloride (up to 1,500%).
Aetna alleges this conspiracy exploited market conditions, fostered cronyism, and suppressed competition, while depriving third-party payers like Aetna of expected cost savings.
According to the complaint, the defendants utilized secretive methods to implement their price-fixing strategies. These included in-person meetings, private phone calls, and strategic coordination during trade association events. Evidence of collusion was deliberately minimized, with written communications often destroyed to evade detection.
Central to the allegations is the so-called &#8220;fair share&#8221; system, which allocated market share and dictated price increases among competitors. This strategy, referred to as the &#8220;rules of engagement,&#8221; ensured that generic drugmakers avoided undercutting one another, thereby maintaining inflated prices. In some cases, competitors allegedly submitted cover bids to maintain an artificial equilibrium in the market.
The lawsuit highlights Teva Pharmaceuticals as an example of this practice, alleging the company collaborated with select &#8220;high-quality&#8221; competitors to lead and follow each other&#8217;s price hikes.
This agreement reportedly extended to various drugs, enabling the companies to dominate the market and secure extraordinary profits.
Aetna contends that the defendants&#8217; actions have severely impacted the U.S. healthcare system, driving up costs for insurers, consumers, and government programs like Medicare Part D.
The insurer is seeking treble damages and injunctive relief under state antitrust and unfair competition laws to recover losses and prevent future anticompetitive practices.
Price Action: CVS stock is up 2.31% at $46.85 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42813560/extended-pfizers-antiviral-paxlovid-use-shows-mixed-results-for-long-covid-relief-study" target="_blank" rel="noreferrer noopener">Pfizer Antiviral Paxlovid&#8217;s Extended Use Shows Mixed Results for Long COVID Relief: Study</a></li>
</ul>
Image: Shutterstock

AMRX

VTRS

CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices

In December, Danish pharmaceutical giant Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) submitted a Citizen Petition to the FDA requesting the exclusion of liraglutide from the 503B Bulks List, a registry of substances that outsourcing facilities may use in drug compounding.
The petition argues that FDA-approved liraglutide-based products, Victoza, Saxenda, and Xultophy, meet the needs of patients without requiring additional compounded versions, which Novo Nordisk contends pose significant safety and efficacy risks.
Teva Pharmaceuticals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) markets an authorized generic of Victoza.
A Phase 2b clinical trial presented at the Alzheimer's Association International Conference 2024 revealed that&nbsp;liraglutide may slow cognitive decline by <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/40047612/novo-nordisks-older-weight-loss-drug-may-slow-cognitive-decline-in-alzheimers-patients-small-stud" rel="noreferrer noopener">protecting the brain</a>.
The company highlights that existing FDA-approved formulations lack attributes that would necessitate compounding, while the Outsourcing Facilities Association&#8217;s (OFA) nomination relies on generalized, unsupported claims.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39487352/novo-nordisks-older-generation-weight-loss-drug-saxenda-associated-with-decreased-bone-mass-densi" rel="noreferrer noopener">Novo Nordisk&#8217;s Older Generation Weight-Loss Drug Saxenda Associated With Decreased Bone Mass Density, Study Shows</a>
Novo Nordisk asserts that compounded liraglutide products have a history of safety concerns, including adverse events and immunogenicity risks stemming from impurities and fibril formation.
The petition cites evidence of unapproved liraglutide products&#8217; <a target="_blank" href="https://www.benzinga.com/markets/equities/24/09/40809053/novo-nordisk-reports-positive-results-of-weight-loss-drug-liraglutide-for-children-as-young-as-6" rel="noreferrer noopener">instability and diminished potency</a>.
Testing has shown reduced bioavailability due to impurities and fibril formation, rendering these products less effective or ineffective for conditions such as type 2 diabetes, cardiovascular disease, and chronic weight management.
Novo Nordisk also <a target="_blank" href="https://www.regulations.gov/document/FDA-2024-P-5966-0001" rel="noreferrer noopener">noted</a> 44 documented adverse events associated with compounded liraglutide since 2017, including 38 serious cases and one death.
Novo Nordisk warns that adding liraglutide to the 503B Bulks List would contradict Congress&#8217; and the FDA&#8217;s intent to restrict patient exposure to unapproved drugs.
The company argues that such an action would undermine incentives for pharmaceutical innovation while increasing risks to public health.
Novo Nordisk further calls for rescission of the FDA&#8217;s 503B Interim Policy, which it claims creates unauthorized pathways for compounding drugs without statutory approval.
The petition also urges the FDA to refrain from categorizing liraglutide under the 503B Interim Policy&#8217;s Category 1, including substances with pending clinical need evaluations.
Novo Nordisk highlights OFA&#8217;s failure to provide adequate data justifying liraglutide&#8217;s inclusion and the risks posed by unapproved compounded products, suggesting that liraglutide be placed in Category 2 due to its significant safety risks.
Price Action: NVO stock is down 0.46% at $87.25 during the premarket session at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42809473/united-airlines-plans-first-starlink-equipped-commercial-flight-this-spring" target="_blank" rel="noreferrer noopener">United Airlines Plans First Starlink-Equipped Commercial Flight This Spring</a></li>
</ul>
Photo via Shutterstock.

Equities

Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug

Wall Street experienced a <a href="https://www.benzinga.com/news/treasuries/24/12/42674886/santa-rally-kicks-off-on-wall-street-stocks-gain-tesla-soars-bitcoin-hits-98000">positive start to the Santa Rally season</a>, with all major indices and sectors closing higher in a shortened session ahead of the Christmas holiday. The S&amp;P 500 climbed 1.1%, marking its third consecutive session of gains following last week&#8217;s volatile Federal Reserve meeting. Meanwhile, the tech-heavy Nasdaq 100 gained 1.35%, nearly erasing last week&#8217;s losses. The Dow Jones Industrial Average ended the session higher by 0.9%.
These are the top stocks that gained the attention of retail traders and investors throughout the day.
Tesla Inc. surged 7.35% to close at $462.25, reaching an intraday high of $462.78 and a low of $435.14. The stock has a 52-week high of $488.54 and a low of $138.80. CEO Elon Musk stated that Tesla could <a href="https://www.benzinga.com/24/12/42667044/teslas-valuation-could-exceed-all-transport-companies-but-spacex-ceo-elon-musk">surpass the value</a> of all transport companies except SpaceX, provided there is a lot of work and good ideas.
Avinger Inc. soared 125.72% to $1.45, with an intraday high of $1.93 and a low of $1.01. The stock&#8217;s 52-week high is $5.45, and the low is $0.39. The company said last week that it had <a href="https://www.benzinga.com/24/12/42666807/why-carbon-revolution-shares-are-trading-higher-by-around-62-here-are-20-stocks-moving-premarket">received a Notice of Allowance</a> for a U.S. patent titled "Catheter Device With Detachable Distal End (For The Treatment Of Peripheral Artery Disease)."
Jet.AI Inc. jumped 79.24% to $6.13, hitting an intraday high of $9.99 and a low of $5.85. The stock&#8217;s 52-week high is $607.51, with a low of $3.29. The company launched &#8220;Ava,&#8221; an advanced AI model designed to <a href="https://www.benzinga.com/news/small-cap/24/12/42674451/why-is-jet-ai-stock-trading-over-100-on-tuesday">streamline private jet bookings</a>, which significantly boosted its stock.
Teva Pharmaceutical Industries Limited saw a modest increase of 0.95% to $22.42, with an intraday high of $22.50 and a low of $22.19. The stock&#8217;s 52-week high is $22.50, and the low is $10.34. Stanley Druckenmiller&#8217;s Duquesne Family Office <a href="https://www.benzinga.com/24/12/42668157/stanley-druckenmiller-offloads-streets-hottest-ai-stocks-heres-what-the-billionaire-investor-is-loading-up-on">increased its stake</a> in Teva Pharmaceutical by acquiring over 1.4 million shares in the third quarter.
Netflix Inc. rose 2.27% to $932.12, reaching an intraday high of $935.85 and a low of $911.70. The stock&#8217;s 52-week high is $941.75, with a low of $461.86. Netflix recently <a href="https://www.benzinga.com/24/12/42675098/netflix-takes-vmware-to-court-over-patent-infringement-claims">filed a lawsuit</a> against Broadcom&#8217;s subsidiary VMware over patent infringement, which could impact future operations.
Prepare for the day&#8217;s trading&nbsp;<a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News">with top premarket movers and news</a>&nbsp;by Benzinga.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42639340/bernie-sanders-is-all-for-canada-becoming-the-51st-state-if-the-u-s-will-also-adopt-universal-healthcare?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bernie Sanders Is &#8216;All For&#8217; Canada Becoming The 51st State If The U.S. Will Also Adopt Universal Healthcare</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

AVGR

JTAI

NFLX

TSLA

Tesla, Avinger, Jet.Ai, Teva, And Netflix: Why These 5 Stocks Are On Investors' Radars Ahead Of Christmas

Billionaire investor Stanley Druckenmiller's family office Duquesne has offloaded two of Wall Street's hottest AI stocks – Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), according to a recent 13F filing.
What Happened: Druckenmiller&#8217;s Duquesne Family Office sold all of its Nvidia shares and significantly reduced its Palantir holdings by 95% during the third quarter.
This comes after Nvidia and Palantir have been on a tear this year. While the Nvidia stock surged nearly 190% in 2024 so far, Palantir shares have gained over 386% to date.
While it's not clear why Duquesne has offloaded these two red-hot AI stocks, profit booking could be one of the motives.
Nvidia and Palantir's relatively rich valuations could also have contributed to Duquesne paring its holdings – while Nvidia's trailing 12 months (TTM) price-to-earnings (PE) ratio stands at 55.21, Palantir's stands at 403.45.
Meanwhile, Druckenmiller is increasing his stake in Teva Pharmaceutical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), a company that has seen its shares rise by 112% this year.
Teva&#8217;s strategic shift towards brand-name therapies and its resolution of opioid litigation as key factors contributing to its recent success.
Druckenmiller&#8217;s fund added 1,427,950 shares of Teva during the September-ended quarter, signaling confidence in the pharmaceutical company&#8217;s turnaround and growth potential.
See Also:&nbsp;<a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42545656/bitcoin-is-no-manhattan-real-estate-peter-schiff-challenges-microstrategys-micheal-saylor-btc-doesnt-generate-any-income" target="_blank" rel="noreferrer noopener">Bitcoin Is No Manhattan Real Estate, Peter Schiff Challenges MicroStrategy's Michael Saylor: ‘BTC Doesn't Generate Any Income'</a>
Why It Matters:&nbsp;Druckenmiller, a protégé of&nbsp;George Soros, is renowned for his macroeconomic investment strategy, often making significant bets on industry trends rather than individual companies.
His recent decision to pivot from AI to pharmaceuticals marks a notable shift in his investment focus. Earlier this year, Druckenmiller <a href="https://www.benzinga.com/24/12/42659876/stanley-druckenmiller-pours-funds-into-1-trillion-company-already-trading-up-100">increased his stake</a> in&nbsp;Broadcom Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), a semiconductor giant, demonstrating his interest in high-growth sectors.
In February, <a href="https://www.benzinga.com/markets/equities/24/02/37175336/billionaire-investor-stanley-druckenmillers-firm-dumps-alphabet-amazon-boosts-investments-in-ai-">Druckenmiller&#8217;s firm divested from</a>&nbsp;Alphabet Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and&nbsp;Amazon.com Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) while <a href="https://www.benzinga.com/markets/equities/24/02/37175336/billionaire-investor-stanley-druckenmillers-firm-dumps-alphabet-amazon-boosts-investments-in-ai-">bolstering investments in AI leaders</a> like&nbsp;Microsoft Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and&nbsp;Nvidia.
Despite his bullish stance on AI, Druckenmiller&#8217;s recent actions suggest a <a href="https://www.benzinga.com/general/health-care/24/12/42627207/stanley-druckenmillers-top-holding-has-outperformed-its-sector-by-252">strategic realignment towards</a> the healthcare sector, particularly in companies like&nbsp;Natera Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), which has outperformed its sector significantly.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42495782/crypto-market-predicted-to-surge-to-all-time-highs-by-late-2025-but-a-30-drop-in-bitcoin-prices-could-come-first" target="_blank" rel="noreferrer noopener">Crypto Market Predicted To Surge To All-Time Highs By Late 2025, But A 30% Drop In Bitcoin Prices Could Come First</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Wikimedia

AMZN

AVGO

GOOG

GOOGL

MSFT

PLTR

Stanley Druckenmiller Dumps Street's Hottest AI Stocks — Here's What The Billionaire Investor Is Betting On Next

According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025.
Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector's performance relative to the S&amp;P 500.
In 2024, biopharma stocks rose by 9.6%, falling short of the S&amp;P 500's 28.5% surge. However, JP Morgan analysts maintain a positive outlook for several key players.
Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), a top pick for the firm, is projected to see continued growth in its diabetes and obesity treatments, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua" rel="noreferrer noopener">Mounjaro and Zepbound</a>. The analyst also pointed to the company's robust pipeline and forecasted double-digit revenue and earnings growth into the 2030s.
Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) has been added to JP Morgan's Analyst Focus List due to the strong potential of its schizophrenia drug, Cobenfy, which could achieve peak sales of $10 billion.
Similarly, Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) are expected to recover in 2025, following challenges in 2024 related to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare" rel="noreferrer noopener">competitive pressures </a>and regional dynamics <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an" rel="noreferrer noopener">affecting key products</a>.
Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is poised for growth with the anticipated mid-2025 launch of lenacapavir <a target="_blank" href="https://www.benzinga.com/quote/GILD" rel="noreferrer noopener">for HIV prevention</a>.
The firm also highlighted AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) for its appealing valuation, supported by strong Skyrizi and Rinvoq sales despite fewer near-term <a target="_blank" href="https://www.benzinga.com/quote/ABBV" rel="noreferrer noopener">pipeline developments</a>.
Animal health stocks are also projected to rebound in 2025. JP Morgan views Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) as the strongest pick in the sector, citing its potential for high single-digit revenue <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" rel="noreferrer noopener">growth and margin expansion</a>. IDEXX Laboratories, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) is another solid choice, though its performance depends on a r<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" rel="noreferrer noopener">ecovery in veterinary visits</a>. Meanwhile, Elanco Animal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) faces uncertainties linked to its <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" rel="noreferrer noopener">new product launches</a>.
Specialty pharmaceuticals showed early signs of stabilization in 2024, benefiting from improved pricing stability and supply dynamics. Perrigo Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) and Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) are highlighted as promising opportunities, while Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) may face growth challenges despite delivering strong clinical trial <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" rel="noreferrer noopener">results this year</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42623487/jp-morgan-defensive-oil-stocks-to-watch-in-2025-amid-70-brent-forecast" target="_blank" rel="noreferrer noopener">Defensive Oil Stocks To Watch In 2025 Amid $70 Brent Forecast: JP Morgan</a></li>
</ul>
Photo via Shutterstock

Analyst Color

ELAN

GILD

IDXX

PRGO

REGN

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Teva Pharmaceutical Industries Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) stock escalated 33.88% after the company and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced that primary endpoints were met in the Phase 2b trial of Duvakitug for <a href="https://www.benzinga.com//node/42531132" target="_blank" rel="noreferrer noopener">ulcerative colitis and Crohn&#8217;s disease</a>.</li>
<li>Klaviyo, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) shares surged 12.85%.</li>
<li>Olive Garden parent Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) stock rose 12.54% after the company reported better-than-expected second-quarter EPS and <a href="https://www.benzinga.com//node/42585797" target="_blank" rel="noreferrer noopener">issued an FY25 revenue outlook</a>. Several analysts raised the <a href="https://www.benzinga.com/quote/dri/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares upped 10.91%. Stephens &amp; Co. initiated coverage with an Equal-Weight rating and <a href="https://www.benzinga.com/quote/docs/analyst-ratings" target="_blank" rel="noreferrer noopener">a price forecast of $55</a>.</li>
<li>Birkenstock Holding plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) shares increased 9.70% after the company reported better-than-expected fourth-quarter financial results and issued FY25 guidance. Several analysts raised <a href="https://www.benzinga.com//node/42599431" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) stock upped 7.30% after the company reported better-than-expected <a href="https://www.benzinga.com//node/42553094" target="_blank" rel="noreferrer noopener">first-quarter EPS and revenues</a>. Several analysts raised <a href="https://www.benzinga.com/quote/jbl/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Neurocrine Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) stock rose 6.88%. The FDA approved Crenessity (crinecerfont) capsules and oral solution as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients four years of age and older with <a href="https://www.benzinga.com//node/42508449" target="_blank" rel="noreferrer noopener">classic congenital adrenal hyperplasia (CAH).</a></li>
<li>GameStop Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) stock was up 6.54% last week, continuing strength from Q3 earnings.</li>
<li>Dr. Reddy&#8217;s Laboratories Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) stock increased 6.29%.</li>
<li>Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) shares upped 6.13% last week.</li>
</ol>
Photo by Sundry Photography via Shutterstock

Movers

BIRK

CHWY

DOCS

KVYO

NBIX

Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?

Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) and Sanofi SA&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and <a href="https://www.benzinga.com/24/12/42531132/why-are-teva-and-sanofi-stocks-trading-higher-on-tuesday" target="_blank" rel="noreferrer noopener">Crohn&#8217;s disease (CD)</a>.
In the RELIEVE UCCD study, 36.2% (low-dose) and 47.8% (high-dose) of patients with ulcerative colitis treated with duvakitug achieved clinical remission compared to 20.45% on placebo, placebo-adjusted rates were 15.7% (low dose) and 27.4% (high dose), at week 14.
BofA Securities raised the price target for Teva to $25 from $23 <a target="_blank" href="https://www.benzinga.com/quote/TEVA/analyst-ratings" rel="noreferrer noopener">with a Buy rating</a>, reflecting a strong Phase 2 data update for duvakitug in inflammatory bowel disorders (IBD).
Based on the strength of the data and the emerging product prole, the analyst forecasts nominal peak sales of ~$2 billion (booked by partner), with Teva booking half the profits.
Given the anticipated impact on profits by 2030, BofA factors in the long-term strength of Teva&#8217;s innovative portfolio by applying a valuation multiple of 9.25x to 2025 estimated EV/EBITDA.
Partnership milestone payments provide reliable cash flow, and the analyst sees potential for the stock to gain value as the company shifts toward growth-focused execution.
The TL1a drug class has emerged over the last two years, led by Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) Prometheus&#8217; strong Phase 2 data, which was followed by similar data from Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) competitor asset.
BofA writes that TL1a was a class of drug that could offer a very good safety profile, on par with market-leading Takeda Pharmaceutical Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) Entyvio, plus a high rate of efficacy across all major patient subgroups.
Data update from Teva in around 240 patients in Phase 2 showed 16%-27% placebo-adjusted MAYO remission scores in the UC population, with the high dose compared favorably to competitors.
TEVA Price Action: Teva Pharmaceutical stock is up 3.23% at $21.56 at publication Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42557565/ozempic-maker-novo-nordisks-poised-to-go-under-european-review-for-potential-increased-risk-of-rare-eye-disease" target="_blank" rel="noreferrer noopener">Novo Nordisk&#8217;s Ozempic Under Scrutiny For Potential Increased Risk Of Rare-Eye Disease</a></li>
</ul>
Photo: Courtey Teva Pharmaceutical Industries

RHHBY

Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases

DARE

ENDPQ

U.S. Supreme Court Agrees To Hear South Carolina's Bid To End Public Funding Of Abortion Provider Planned Parenthood

Wall Street experienced a downturn on Tuesday as major indices fell following a strong retail sales report for November. The data raised concerns about the Federal Reserve&#8217;s potential delay in cutting interest rates next year. The S&amp;P 500 and Dow Jones Industrial Average dropped by 0.4% and 0.6% respectively, while the Nasdaq 100 declined by 0.3%, with semiconductor stocks leading the losses amid geopolitical tensions.
These are the top stocks that gained the attention of retail traders and investors through the day:
Nukkleus Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>)
Nukkleus Inc. saw a significant surge of 754.68%, closing at $11.88. The stock reached an intraday high of $17.66 and a low of $1.84, with a 52-week range of $34.16 to $0.40. This dramatic rise followed the company&#8217;s announcement of acquiring a 51% controlling stake in Star 26 Capital Inc., which holds a substantial share in RIMON, an Israeli supplier for the Iron Dome missile defense system. This acquisition <a href="https://www.benzinga.com/24/12/42535878/why-nukkleus-stock-is-gaining-tuesday">boosts</a> Nukkleus&#8217;s defense ambitions.
Micron Technology Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>)
Micron Technology Inc. experienced a modest increase of 0.31%, closing at $108.60. The stock fluctuated between a high of $110.49 and a low of $107.68, with a 52-week range of $157.54 to $78.63. The company is set to release its first-quarter financial results, with analysts <a href="https://www.benzinga.com/24/12/42541544/micron-q1-earnings-preview-analyst-estimates-why-company-is-well-positioned-heading-into-2025">expecting revenue</a> to reach $8.72 billion, a significant increase from the previous year. Micron has consistently outperformed revenue estimates in recent quarters.
Teva Pharmaceutical Industries Ltd.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>)
Teva Pharmaceutical Industries Ltd. saw its stock rise by 26.47%, closing at $20.88. The stock hit an intraday high of $21.05 and a low of $19.03, with a 52-week high of $21.05 and a low of $10. The increase followed the successful completion of a Phase 2b study for a monoclonal antibody targeting inflammatory bowel disease, achieving&nbsp;<a href="https://www.benzinga.com/24/12/42531132/why-are-teva-and-sanofi-stocks-trading-higher-on-tuesday">positive</a>&nbsp;results in clinical remission rates.
Quantum Computing Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>)
Quantum Computing Inc. shares jumped by 51.53%, closing at $16.79. The stock&#8217;s intraday range was $18.06 to $12.60, with a 52-week high of $18.06 and a low of $0.35. The rise came after the company announced a <a href="https://www.benzinga.com/24/12/42533581/quantum-computing-stock-is-rising-tuesday-heres-why">prime contract</a> with NASA for imaging and data processing support, utilizing its Dirac-3 machine to enhance data quality and accuracy.
Tesla Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
Tesla Inc. saw a 3.64% increase, closing at $479.86. The stock reached an intraday high of $483.99 and a low of $457.51, with a 52-week range of $483.99 to $138.8. Analyst Dan Ives predicts that Tesla will be a <a href="https://www.benzinga.com/markets/equities/24/12/42522531/tesla-will-be-the-biggest-winner-in-the-trump-era-says-dan-ives-predicts-nasdaq-at-25000-in-18-months-get-the-popcorn-out">major beneficiary</a> in the tech sector expansion anticipated under President-elect Donald Trump&#8217;s administration, driven by artificial intelligence and deregulation.
Image Via Shutterstock.com
Prepare for the day&#8217;s trading&nbsp;<a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News">with top premarket movers and news</a>&nbsp;by Benzinga.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/12/42485284/billionaire-warren-buffett-paid-120000-for-a-home-but-took-out-a-mortgage-to-do-it-investing-that-money-instead-made-him-2-billion?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Billionaire Warren Buffett Paid $120,000 For A Home But Took Out A Mortgage To Do It – Investing That Money Instead Made Him $2 Billion</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

NUKK

QUBT

Nukkleus, Micron, Teva Pharmaceutical, Quantum Computing, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Teva inks partnership with Klinge to launch Eylea biosimilar in Europe

Teva (TEVA) announced that it has entered into a strategic collaboration with Klinge Biopharma and Formycon for the semi-exclusive commercializatio...

Teva enters pact with Klinge Biopharma, Formycon to commercialize FYB203

Analyst Jason Gerberry from Bank of America Securities reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report) and increased the pr...

Teva Pharmaceutical's Growth Potential and Strategic Market Positioning

Teva Pharmaceutical Industries Limited (TEVA) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Bullish option flow detected in Teva (TEVA) with 28,557 calls trading, 1.5x expected, and implied vol increasing almost 16 points to 57.61%. Jan-25...

Teva call volume above normal and directionally bullish

AbbVie retains Humira market share above 70%: report

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price targe...

Barclays Remains a Buy on Teva Pharmaceutical (TEVA)

The Department of Health and Human Services, through the Centers for Medicare & Medicaid Services, announced the selection of 15 additional drugs c...

Ozempic, Xtandi among next 15 drugs selected for U.S. price talks

Pharma lobby slams IRA, PBMs as Medicare lists 15 more drugs for price setting

Teva sues CMS over Medicare drug price negotiations

ALPMF

ALPMY

ALVO

AZNCF

IRWD

SDZXF

TBPH

TEVJF

Press Releases

Teva to Present at the Jefferies London Healthcare Conference

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States

Teva Announces Collaboration to Commercialize Formycon's Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Teva Pharmaceutical Indus

ニュース

最新ニュース Teva Pharmaceutical Indus (NYSE:TEVA) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル